# CVS Health Split Fails to Address Core Structural Issues The proposed corporate separation ignores the systemic problems inherent in pharmacy benefit management operations. - **Source:** [STAT](https://www.statnews.com) - **Published:** 2026-11-09 - **Topic:** [Business](https://brifing.si/c/business) - **Original article:** - **On Brifing:** https://brifing.si/s/f4e6d4c7-6a9a-433e-bed2-2acdf4299165 ## Corporate Restructuring Announcement CVS Health recently announced a significant plan to split its massive operations into two separate entities. As one of the largest companies in the United States, the firm generates over $400 billion in annual revenue. This move follows intense public and regulatory scrutiny regarding its extensive influence across the national drug supply chain. ## Misinterpretation of Strategic Intent Media coverage often frames this separation as a direct response to regulatory pressure aimed at unwinding vertical integration. However, this interpretation overlooks the underlying business strategy. The split does not necessarily dismantle the integrated power structures that currently define the company's market position or its operational control over pharmaceutical distribution channels. ## Pharmacy Benefit Management Dominance Pharmacy Benefit Managers, or PBMs, remain a central component of the company's financial model. These entities act as intermediaries between drug manufacturers and insurers, often dictating costs for millions of Americans. Despite the corporate split, these intermediaries continue to benefit financially from the existing complexities within the current healthcare pricing system. ## Systemic Healthcare Supply Chain CVS Health maintains a presence in nearly every segment of the American drug supply chain. This deep integration allows the company to influence pricing and access for hundreds of millions of patients annually. The proposed split does not fundamentally alter the mechanics of how these drugs reach consumers or their final costs. ## Regulatory Pressure and Oversight Ongoing regulatory scrutiny has targeted the opaque nature of PBM operations and their impact on consumer drug prices. While the split might satisfy certain governance requirements, it does not address the core criticisms regarding transparency. Regulators remain concerned about how these entities leverage their market size to influence healthcare affordability nationwide. ## Financial Scale and Impact With annual revenues exceeding $400 billion, the scale of CVS Health makes any structural change a matter of national economic interest. The company serves a vast portion of the U.S. population, meaning its internal reorganizations have ripple effects across the entire healthcare sector. Investors are watching how these two entities will operate. ## Limitations of Corporate Splitting Splitting a company into two parts does not automatically resolve the fundamental problems associated with vertical integration. If the underlying business practices remain unchanged, the consumer experience regarding drug costs will likely stay the same. The structural separation appears to be a cosmetic change rather than a shift in operational philosophy. ## Future Industry Outlook Observers should monitor whether this split leads to genuine competition or simply creates two dominant entities instead of one. The true test will be if the new structure reduces the financial burden on average Americans. Without significant changes to PBM practices, the fundamental issues within the healthcare supply chain will persist. ## Sources covering this story - https://www.statnews.com/2026/11/09/cvs-health-split-pbm-conflict-examined-anthony-loiacono-judi-health/?utm_campaign=rss — --- _Summary written by Brifing from the original reporting. Copyright in the original article belongs to its publisher; read the full piece at the link above._